Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215829 | 0.92 | NCF1 (0.58) | ADRA2CMAPTGAAKDM4EALDH1A1 | |
| SCHEMBL5795262 | 0.88 | — | — | |
| SCHEMBL10673891 | 0.88 | ALDH1A1 (0.55) | ADRA2CMAPTGAAKDM4EALDH1A1 | |
| SCHEMBL281977 | 0.83 | L3MBTL3 (0.55) | ADRA2CMAPTGAAKDM4EALDH1A1 | |
| SCHEMBL27879361 | 0.82 | L3MBTL3 (0.53) | MAPTGAAALDH1A1KMT2A | |
| SCHEMBL1444158 | 0.79 | LMNA (0.52) | MAPTGAAKDM4EALDH1A1KMT2A | |
| SCHEMBL114702 | 0.78 | CHKA (0.46) | MAPTGAAKDM4EALDH1A1KMT2A | |
| SCHEMBL41297 | 0.78 | CHKA (0.52) | MAPTGAAKDM4EALDH1A1KMT2A | |
| SCHEMBL4576289 | 0.78 | DRD2 (0.68) | MAPTGAAKDM4EGFERSMN1; SMN2 | |
| SCHEMBL27853947 | 0.77 | F2 (0.38) | ADRA2CMAPTGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145505-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| CN-118255727-A | Compound containing anthraquinone ring parent nucleus, preparation method and application thereof | 杭州市第一人民医院 | 2024-06-28 | — | — | CN | claimed |
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-06-18 | — | — | US | claimed |
| CN-112574123-B | JNK inhibitors, pharmaceutical compositions and uses thereof | 武汉朗来科技发展有限公司 | 2024-06-11 | — | — | CN | claimed |
| EP-4352059-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2024-04-17 | — | — | EP | claimed |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | claimed |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-22 | — | — | US | claimed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | claimed |
| WO-2024009308-A1 | TRPV2 CHANNEL BLOCKERS AND USE THEREOF | ICHILOV TECH LTD. (IL) | 2024-01-11 | — | — | WO | claimed |
| WO-2023217539-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2023-11-16 | — | — | WO | claimed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | claimed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | claimed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | claimed |
| EP-0973761-B1 | RED COLOURING HYPERCHROMIC 3H-NAPHTHO 2,1-b ]PYRANS | JAMES ROBINSON LTD (GB) | 2002-07-03 | — | — | EP | claimed |
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | claimed |
| US-6294112-B1 | Red coloring hyperchromic 3H-naphtho[2,1-B]pyrans | JAMES ROBINSON LIMITED (GB) | 2001-09-25 | — | — | US | claimed |
| EP-0973761-A1 | RED COLOURING HYPERCHROMIC 3$i(H)-NAPHTHO 2,1-$i(b)]PYRANS | JAMES ROBINSON LIMITED (GB) | 2000-01-26 | — | — | EP | claimed |
| EP-0351856-B1 | Thiazolo[5,4-b]azepine compounds | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-09-15 | — | — | EP | claimed |
| WO-1998045281-A1 | RED COLOURING HYPERCHROMIC 3H-NAPHTHO[2,1-b]PYRANS | JAMES ROBINSON LIMITED (GB) | 1998-10-15 | — | — | WO | claimed |
| US-4716168-A | STIMULANTS OF IMMUNE RESPONSE | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1987-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR2, FGFR1 | ADRA2C 4350/4885MAPT 4465/4885GAA 647/4885 |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | ADRA2C 4507/4885MAPT 4197/4885GAA 426/4885 |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | EGFR, ERBB2, ERBB3 | ADRA2C 3248/4885MAPT 4295/4885GAA 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.